Is GGT a better monitoring choice than albumin-to-creatinine ratio on retatrutide?

What I have: GGT · albumin-to-creatinine ratio · retatrutide.

I would like the axes of comparison first and the recommendation second.

I have tried the first option and it works; the question is whether the second is better rather than merely different.

Under what conditions does the answer flip?

The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.

Decide the action for each result before you order the test.

The relevant statistical point is that a ninety-five per cent reference interval means one analyte in twenty will read out of range in a healthy person by construction.

A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Mechanically, a twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.

Keep the full report, not the number. You will need the units and the interval later.

edited 2 Sept 2024 by Dr_Bram_Verhoeven — added the citation requested in comments

The short version: a small, well-chosen panel with a baseline beats a large one without.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.

Research-use compounds are not approved for human use, and no panel makes that safer.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.

Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

SELECT reported a hazard ratio of 0.80 (95% CI 0.72–0.90) for the primary composite major adverse cardiovascular event endpoint with semaglutide 2.4 mg in overweight or obese adults with established cardiovascular disease and without diabetes[1].

Baseline first, then a repeat under identical conditions. Everything else is secondary.